"Straight up dilution?" It is and it isn't.
Post# of 72440
If one looks at the selling of more shares in isolation from all other factors, yes it is dilution. There are many small biotech firms continually churning out more shares to pay salaries and bonuses without advancing their drugs thru clinical trials (think NNAB here as one egregious example) or even conducting clinical trials. IPIX does not operate like that.
However, if you look at the advancement of our scientific trials and drugs as the commodity being purchased, the actual value of each of our shares is increasing, even though there may be more of them. It would not do for IPIX to run out of funds.